Critical Review: Cellular Dynamics International (ICEL) vs. Its Peers

Cellular Dynamics International (NASDAQ: ICEL) is one of 8 publicly-traded companies in the “Biotechnology & Medical Research – NEC” industry, but how does it weigh in compared to its rivals? We will compare Cellular Dynamics International to similar companies based on the strength of its profitability, earnings, valuation, dividends, institutional ownership, risk and analyst recommendations.

Insider & Institutional Ownership

38.2% of shares of all “Biotechnology & Medical Research – NEC” companies are owned by institutional investors. 10.2% of shares of all “Biotechnology & Medical Research – NEC” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Cellular Dynamics International and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellular Dynamics International 0 0 0 0 N/A
Cellular Dynamics International Competitors 11 93 176 1 2.59

As a group, “Biotechnology & Medical Research – NEC” companies have a potential upside of 207.37%. Given Cellular Dynamics International’s rivals higher possible upside, analysts plainly believe Cellular Dynamics International has less favorable growth aspects than its rivals.


This table compares Cellular Dynamics International and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellular Dynamics International -88.12% -57.59% -38.09%
Cellular Dynamics International Competitors -50.37% -44.87% -19.68%

Earnings and Valuation

This table compares Cellular Dynamics International and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cellular Dynamics International N/A N/A -8.53
Cellular Dynamics International Competitors $2.54 million -$38.02 million -5.42

Cellular Dynamics International’s rivals have higher revenue, but lower earnings than Cellular Dynamics International. Cellular Dynamics International is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


Cellular Dynamics International rivals beat Cellular Dynamics International on 8 of the 8 factors compared.

About Cellular Dynamics International

Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company’s products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.

Receive News & Ratings for Cellular Dynamics International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Dynamics International and related companies with's FREE daily email newsletter.

Leave a Reply